Apax Partners Leads Spin-Out of Biomarker Discovery Company Sense Proteomic
News Jun 09, 2008
Sense Proteomic Ltd. has announced its spin out and its creation as a biomarker discovery company. It will now be focusing on using its proprietary protein array platform to discover novel panels of auto-antibody biomarkers in cancer and autoimmune diseases.
Sense Proteomic was previously a subsidiary of the biosciences tools business Procognia Ltd, whose other subsidiary was listed on the Tel-Aviv stock exchange in 2007.
Commenting on the deal, Amos Goren, of Apax, said, “Apax is pleased to be supporting the new management team of Sense Proteomic as they develop this exciting business. It is our belief that over the next few years growth in the diagnostic industry will revolutionize healthcare by enabling earlier and more targeted treatment of disease.”
Rachel Fallon Joint CEO said, “Apax’s support will allow us to accelerate our biomarker programmes to validate the strong data we already have in both autoimmune diseases and cancer. This will allow us to maintain our position as leaders in the field.”
Chris Lyddon, Sense Proteomic’s other Joint CEO, added “I am delighted that Apax has invested in Sense Proteomic, their support endorses both our technical approach and our business model”.
Nonalcoholic fatty liver disease produces no noticeable symptoms, but one out of every five people with it will go on to develop a more serious conditions such as nonalcoholic steatohepatosis and cirrhosis. Three new studies investigate how mitochondrial energy production is altered by the progress of fatty liver disease.READ MORE